Physician profile
Catherine E Vitosh
NPI 1124181573
$1,825.33
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $653 · 2021: $529 · 2022: $130.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $283.68 | 2019-2021 | |
| Abbvie INC. | $205.30 | 2019-2022 | |
| Astellas Pharma US INC | $171.07 | 2019-2022 | |
| Novo Nordisk INC | $169.65 | 2019-2021 | |
| Allergan, INC. | $127.78 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.87 | 2019-2022 | |
| Amarin Pharma, INC. | $89.20 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $83.24 | 2020-2022 | |
| Lilly USA, LLC | $76.15 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $61.97 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.48 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $49.19 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $40.00 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $38.97 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.69 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $33.71 | 2019 | |
| Daiichi Sankyo INC. | $26.80 | 2019-2021 | |
| Vivus LLC | $19.07 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.67 | 2022 | |
| Esperion Therapeutics, INC. | $18.37 | 2021 | |
| Neos Therapeutics, LP | $17.36 | 2020 | |
| Sanofi Pasteur INC. | $15.41 | 2021 | |
| Collegium Pharmaceutical, INC. | $15.04 | 2020 | |
| Bioventus LLC | $14.36 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.21 | 2020 | |
| Ironwood Pharmaceuticals, INC | $14.13 | 2020 | |
| Genentech USA, INC. | $13.61 | 2019 | |
| Mylan Specialty L.P. | $13.47 | 2022 | |
| Pfizer INC. | $10.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Vitosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.